- Home
- PCRX vs FFWM Comparison
PCRX vs FFWM Comparison
Compare PCRX & FFWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- FFWM
- Stock Information
- Founded
- PCRX 2006
- FFWM 1990
- Country
- PCRX United States
- FFWM United States
- Employees
- PCRX N/A
- FFWM N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- FFWM Major Banks
- Sector
- PCRX Health Care
- FFWM Finance
- Exchange
- PCRX Nasdaq
- FFWM Nasdaq
- Market Cap
- PCRX 1.2B
- FFWM 378.0M
- IPO Year
- PCRX 2011
- FFWM 2014
- Fundamental
- Price
- PCRX $24.02
- FFWM $5.18
- Analyst Decision
- PCRX Buy
- FFWM Buy
- Analyst Count
- PCRX 9
- FFWM 4
- Target Price
- PCRX $29.89
- FFWM $7.25
- AVG Volume (30 Days)
- PCRX 526.9K
- FFWM 637.3K
- Earning Date
- PCRX 07-29-2025
- FFWM 07-24-2025
- Dividend Yield
- PCRX N/A
- FFWM N/A
- EPS Growth
- PCRX N/A
- FFWM N/A
- EPS
- PCRX N/A
- FFWM N/A
- Revenue
- PCRX $702,772,000.00
- FFWM $113,564,000.00
- Revenue This Year
- PCRX $7.54
- FFWM $182.35
- Revenue Next Year
- PCRX $10.78
- FFWM $7.79
- P/E Ratio
- PCRX N/A
- FFWM N/A
- Revenue Growth
- PCRX 3.08
- FFWM N/A
- 52 Week Low
- PCRX $11.16
- FFWM $4.42
- 52 Week High
- PCRX $29.33
- FFWM $8.52
- Technical
- Relative Strength Index (RSI)
- PCRX 36.83
- FFWM 52.48
- Support Level
- PCRX $23.85
- FFWM $5.00
- Resistance Level
- PCRX $25.16
- FFWM $5.32
- Average True Range (ATR)
- PCRX 0.79
- FFWM 0.17
- MACD
- PCRX -0.12
- FFWM -0.01
- Stochastic Oscillator
- PCRX 8.20
- FFWM 45.87
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.